ArticleScientific reports2026
Structure-guided analysis of divergent homologs unveils deep ancestry and arthropod specialization of the pacifastin family.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Pacifastin family has been widely regarded as an arthropod-specific innovation, functionally restricted to the regulation of innate immunity. Here, we challenge this paradigm using a structural phylogenomics approach that overcomes the sequence erosion characteristic of small disulfide-rich proteins. We identified a population of "cryptic" homologues comprising ~ 30% of the dataset-undetectable by sequence alone and demonstrated that the characteristic Pacifastin's six-cysteine scaffold is not an arthropod invention but an ancient lineage whose evolutionary roots extend across major metazoan phyla, Fungi, and Bacteria. Structural and architectural profiling revealed two recurrent organizational modes: an ancestral class characterized by an N-terminal β-hairpin extension, glycine-rich and frequently embedded in multidomain, extracellular matrix-associated proteins, and a conventional, derived arthropod-restricted class characterized by modular simplification and predicted structural rigidity consistent with a soluble-effector function. We propose a "Liberation and Structural Convergence" evolutionary model to explain this transition: the acquisition of proteolytic processing sites in inter-domain linkers is consistent with a mechanism by which arthropods may have released these domains from the matrix, while the concurrent structural convergence is consistent with adaptation to a soluble, circulating hemolymph environment. Further phylogenomic profiling of the reactive site revealed a functional shift from an ancestral inhibitory signature enriched in basic and charged residues to a derived arthropod-specific radiation toward hydrophobic residues. This transition suggests a broadening of target specificity toward chymotrypsin- and elastase-like proteases, consistent with the recruitment of these inhibitors into arthropod immune roles. Together, these results reposition pacifastins as an ancient protein lineage and illustrate how modularity, proteolytic processing, and biophysical constraints may have driven the transition from matrix-embedded regulatory scaffolds to systemic soluble effectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.